Chronic administration of clenbuterol (CB), a lipophilic b 2 -adrenoceptor (b 2 -AR) agonist, induces skeletal muscle hypertrophy and slow-to-fast fiber-type transitions in mammalian species, but the mechanism and pathophysiological roles of these changes have not been explored.
Introduction
Skeletal muscle contains mostly b 2 -adrenoceptor (b 2 -AR), together with less than 10% b 1 -AR, as well as a small population of a-AR (1 -3) . Many studies have shown that chronic administration of clenbuterol (CB), a b 2 -AR agonist, can induce skeletal muscle hypertrophy in multiple mammalian species, including humans (4 -6) . As a consequence of its muscle anabolic properties, CB might have therapeutic potential for the treat-ment of muscle wasting associated with sarcopenia, cancer cachexia, sepsis, denervation, disuse, inactivity, unloading, microgravity, or heart failure, although it is necessary to obviate cardiovascular side-effects (4) . The b 2 -adrenergic signaling pathways responsible for CB-induced hypertrophy have been well studied, often with the aim of identifying novel therapeutic targets for the treatment of muscle-wasting disorders, and it appears that b 2 -AR stimulation with CB can increase protein synthesis and inhibit protein degradation through activation of the Akt and/or protein kinase A signaling pathways (4, 7) . Adult skeletal muscle is composed of muscle fibers that differ in their speed of contraction and predominant type of energy metabolism. Muscle fibers can be classified as type I, slow-twitch fibers, and type II, fast-twitch fibers, on the basis of their predominant myosin heavy chain (MHC) isoform content. Generally, MHC I and MHC IIa fibers utilize oxidative phosphorylation as their energy source, whereas MHC IId/x and MHC IIb fibers harness anaerobic metabolism to generate ATP (8) . The relative frequency of each muscle fiber type in skeletal muscle defines the overall functional capabilities, and these are affected by neuromuscular activity, aging, exercise training, thyroid hormone, and mechanical loading (9) .
In addition to hypertrophy, chronic administration of CB has been found to induce a slow-to-fast fiber-type transition in skeletal muscle (4, 6) . However, little is known about the mechanisms underlying the CB-induced fiber-type transition. One possibility is that this transition is induced by direct action on muscle b 2 -AR and another possibility is that it is induced by b 2 -AR stimulation in the central nervous system (CNS). In the general fibertype transition scheme, an increase in neuromuscular activity (e.g., endurance exercise or chronic low-frequency electrical stimulation) leads a muscle towards a slower phenotype, changing its MHC composition in a more or less strict sequence towards the slower isoforms (i.e., IIb→IId/x→IIa→I) (10, 11) . The converse response is seen when the muscle is subjected to a decrease in neuromuscular activity (e.g., disuse or denervation). Thus, we hypothesized that chronic administration of CB would cause changes in neuromuscular activity, which might in turn contribute to slow-to-fast MHC transitions. However, the effects of chronic CB treatment on neuromuscular activity have not yet been reported.
Recently, a radio-telemetry system has been developed to record an electromyogram (EMG) continuously over a period of weeks in freely moving animals (12 -16) . It has been used to evaluate the total duration of daily muscle activity (duty time) in masseter muscle of rats and rabbits, and the duty time was found to be correlated with the composition of MHC isoforms (12, 14 -16) .
We have previously demonstrated that bite-opened mechanical loading induces masseter muscle hypertrophy with a fast-to-slow MHC isoform transition and also increases muscle activity by analyzing daily EMG data obtained with a radio-telemetry system in biteopened rats (17) . The results indicated a causal relation between duty time and MHC composition and can be reasonably interpreted in terms of the general fastto-slow fiber-type transition scheme (10, 11) .
In the present study, we examined the effects of CB, a lipophilic b 2 -AR agonist, on the hypertrophy and MHC composition of rat masseter muscle (the principal jaw closer in rodents) by means of SDS-PAGE analysis and on muscle activity by means of EMG analysis with a radio-telemetry system. We also compared the effects of CB with those of salbutamol (SB), a hydrophilic b 2 -AR agonist, to clarify whether these effects occur via direct action on muscle b 2 -AR stimulation or via the CNS.
Materials and Methods

EMG recording with radio-telemetry system
The animal care and experimental protocols were approved by the Animal Care and Use Committee of Tsurumi University. Daily EMGs of freely moving rats were recorded with a radio-telemetry system as described previously (17) . EMG was recorded for 24 h at 1 and 2 weeks after implantation of a transmitter (F50-EEE; Data Sciences International, St. Paul, MN, USA) ( Fig. 1 ), Fig. 1 . Treatment with clenbuterol (CB) or salbutamol (SB) treatment and daily EMG recording using a radio-telemetry recording system. EMG was recorded for 24 h at 1 and 2 weeks after implantation of the telemetry system and these results served as controls (1w Cont, 2w Cont). Treatment with CB or SB was subsequently initiated. CB was administered via the drinking water (30 mg/L) for 2 weeks and SB was administered via intraperitoneal injection (1.15 mg/kg) for 2 weeks. EMG was recorded for 24 h at 1 day, 1 week, and 2 weeks after the initiation of CB or SB treatments (1d CB, 1w CB, 2w CB, 1d SB, 1w SB, 2w SB). and these results served as controls. Subsequently, CB (Sigma, St. Louis, MO, USA) treatment was initiated via the drinking water (30 mg/L) for 2 weeks because oral administration of CB might increase the skeletal mass efficiently without altering the body weight (18, 19) . SB (Sigma) treatment was initiated via intraperitoneal injection (1.15 mg/kg) (20) . EMG was recorded for 24 h at 1 day, 1 week, and 2 weeks after the initiation of treatment ( Fig. 1) (21) . After the recordings, the masseter muscles were excised from the CB-treated and agematched control rats and stored at −85°C.
Histological analysis
Cross sections (10-mm-thick) were cut from the middle portion of the left masseter muscle with a cryostat (CM1900; Leica Microsystems, Nussloch, Germany) at −20°C. The sections were stained with hematoxylin and eosin (HE) and observed under a light microscope (BX61; Olympus Co., Tokyo). Micrographs were taken with a digital camera (DP-72, Olympus Co.) connected to a personal computer. The cross-sectional size of muscle fibers was evaluated by measuring the minimal diameter of muscle fibers in order to correct for obliquely cut muscle fibers (22) . The minimal diameter of 100 muscle fibers in the superficial portion was measured with image analysis software (Image J 1.45) and averaged to obtain the mean value in each rat.
MHC composition
MHC composition was analyzed by means of SDS-PAGE in the right superficial masseter muscles excised from CB-treated and age-matched control rats as described previously (17, 22) .
Muscle activity analysis
Muscle activities were evaluated by analyzing daily EMG with Notocord-hem software (NVC31a; Notocord, Croissy sur Seine, France) (Supplementary Figs. 1 and 2: available in the online version only), as described previously by us and others (17, 23) . Briefly, to determine the total duration (daily duty time) of muscle activity exceeding 5%, 20%, 50%, or 80% of the day's peak EMG levels, the sum of the burst length, as indicated by underlining in Supplementary Fig. 2 , was calculated. The duty time was expressed as a percentage relative to the 24-h period (i.e., the percentage of time the muscle is active at more than 5%, 20%, 50%, or 80% of the day's peak EMG levels). Muscle activity exceeding 80% of the day's peak EMG levels represents only the most forceful muscle activity ( Supplementary Fig. 2E ), while that exceeding 5% of the day's peak EMG levels represents overall muscle activity including not only forceful activity but also low-intensity activity such as postural activity ( Supplementary Fig. 2B ).
Electrocardiogram recording using a telemetric unit
Conscious rats were separately placed in plastic cages, which were placed on a receiver, and data in the freely moving rats were recorded by using the data acquisition system (24, 25) . ECG signals were recorded from the telemetric unit with the use of an under-cage receiver (Data Sciences International), digitized at a sampling rate of 2 kHz, and fed into a microcomputer-based data acquisition system (Power Lab System; AD Instruments, Milford, MA, USA) for 24 h at 1 and 2 weeks after implantation of a telemetric unit and served as controls. Subsequently, it was recorded at 1 day, 1 week, and 2 week after the initiation of CB treatment. ECG signal processing was performed with the software program Chart v5.0 and HRV analysis with the HRV plug-in for Chart v5.0 (AD Instruments).
Statistical analyses
All data are expressed as means and standard error (S.E.). The statistical significance of differences in body weight, masseter muscle mass, masseter mass / body weight ratio, fiber diameter (Figs. 2 and 5, Supplementary  Fig. 3 : available only in the online version only, Table 1 ) and relative proportion of each MHC isoform between CB-treated and age-matched control rats (Figs. 3 and 6) was determined by means of unpaired t-tests. The statistical significance of differences in duty time among the 5 EMG recordings (1w Cont, 2w Cont, 1d CB, 1w CB, and 2w CB) was determined by means of one-factor Supplementary Fig. 4 : available in the online version only).
Results
Effects of CB on masseter muscle
Body weight, masseter muscle mass, and masseter mass to body weight ratio were examined in 2-week CB-treated and age-matched control rats (Fig. 2) . Body weight was similar in each group (Control vs. CB: 370 ± 3.0 g vs. 384 ± 6.7 g, P = NS, not significant, n = 6) ( Fig. 2A ), but the masseter muscle mass (Control vs. CB: 1270 ± 33.7 mg vs. 1789 ± 33.3 mg, P < 0.01, n = 6) ( Fig. 2B ) and the masseter mass to body weight ratio (Control vs. CB: 3.4 ± 0.1 mg/g vs. 4.7 ± 0.1 mg/g, P < 0.01, n = 6) ( Fig. 2C ) were significantly increased by the CB treatment (P < 0.01, n = 6). Histological analysis showed no abnormal organization of masseter structure (such as fibrosis) in either group, but the fiber diameter was significantly greater in the CB-treated group than in the controls (Control vs. CB: 49 ± 3.4 mm vs. 62 ± 4.7 mm, P < 0.05, n = 6) ( Fig. 2 : D and E). We also examined the body weight, masseter muscle mass, masseter mass to body weight ratio, HE staining, and fiber diameter in 1-day CB-treated and age-matched control rats, but there was no difference between the two groups ( Supplementary Fig. 3 ).
Effects of CB on other muscles and heart rate
We also examined the mass of other skeletal muscles (tibialis anterior and soleus) and cardiac muscle at 2 weeks after CB treatment (Table 1 ). Skeletal and cardiac muscle hypertrophy, evaluated in terms of muscle mass to body weight ratio (mg/g), were significantly increased versus the controls (P < 0.001, 0.01, or 0.05, n = 4), and the magnitudes of the increase were similar in the two types of muscle, indicating that the dose of CB used in Fig. 2 . Effects of CB on body weight, masseter mass, and fiber diameter at 2 weeks. Body weight (A), masseter muscle mass (B), and masseter mass to body weight ratio (C) in rats treated with CB for 2 weeks (CB) and age-matched control rats (Control). No significant difference in body weight was observed between the Control and CB group (P = NS, n = 6), while both the masseter muscle mass and the masseter mass to body weight ratio were significantly increased by the CB treatment (**P < 0.01 vs. Control, n = 6). Typical cross-sections of HE staining (D) and the average fiber diameter (E) of masseter muscles in the Control and CB-treated rats. Fiber diameter was significantly increased by CB treatment (Cont vs. CB: 49 ± 3.4 mm vs. 62 ± 4.7 mm, *P < 0.05, n = 6).
this study increased the mass of the skeletal and cardiac muscle efficiently without altering the body weight, probably due to the concomitant decrease of fat tissue induced by CB through its lipolytic effect (18, 19, 26) . We also performed electrocardiogram (ECG) recording using a telemetric unit (24, 25, 27) . ECG was recorded for 24 h at 1 week (1w Cont) and 2 weeks (2w Cont) after implantation of the telemetric unit and these results served as controls. Subsequently, ECG was recorded at 1 day (1d CB), 1 week (1w CB), and 2 weeks (2w CB) after the initiation of CB treatment. Daily mean heart rate was significantly increased from 354 ± 6 bpm (beat/min: 1w Cont) to 419 ± 13 bpm (1d CB) and then remained unchanged in 1w CB (391 ± 8 bpm) and 2w CB (404 ± 7 bpm) (P < 0.05 or 0.01 vs. 1w Cont, n = 4) (Supplementary Fig. 4 ).
Effects of CB on MHC composition of masseter muscle
The average MHC compositions in masseter muscles obtained from 2-week CB-treated and age-matched control rats were examined by SDS-PAGE analysis (Fig. 3) . The masseter muscle consisted of neonatal, IIa, IId/x, and IIb MHC isoforms in each group (Fig. 3A) . MHC I was hardly detectable by SDS-PAGE analysis because its expression was low in the masseter muscle, as previously established (17, 28) . The CB treatment promoted transition of MHC isoforms toward faster muscle phenotypes: the proportion of MHC IIa was significantly decreased from 16% ± 1.5% to 8% ± 1.4% (P < 0.01, n = 6), while that of MHC IIb was significantly increased from 34% ± 2.4% to 46% ± 3.2% (P < 0.05, n = 6) ( Fig. 3B ). Fig. 3 . Effects of CB on MHC composition of masseter muscle. Typical SDS-PAGE profiles of MHC isoforms (A) and the average MHC compositions (B) of masseter muscles from CB-treated (CB) and age-matched control (Control) rats. The relative proportion of each MHC isoform is expressed as a percentage of total MHC content (% of total MHC). The proportion of MHC IIa was significantly decreased from 16% ± 1.5% to 8% ± 1.4% (P < 0.01), while that of MHC IIb was significantly increased from 34% ± 2.4% to 46% ± 3.2% (P < 0.05) after the CB treatment (*P < 0.05, **P < 0.01, n = 6). Fig. 4 . Effects of CB on masseter muscle activity. The average duty times were calculated before and after CB treatment and the proportions of activities exceeding 5%, 20% (A), 50%, and 80% (B) of the day's peak EMG level were determined. The relative duty times are also expressed as a percentage of the respective value in the 1w Cont group set as 100% (C). The average duty times of all four activity levels in the masseter muscle showed no difference between 1w Cont and 2w Cont, but those exceeding 20%, 50%, and 80% of the day's peak EMG were significantly increased at 1 day after the CB treatment (1d CB) and remained unchanged at 1 (1w CB) and 2 weeks (2w CB, P < 0.05 or 0.01 vs. 1w Cont). However, the magnitude of the increase was approximately 6-fold at the higher activity levels (exceeding 50% and 80% of the day's peak activity), whereas it was only approximately 2-fold at lower activity level (exceeding 20% of the day's peak activity) (*P < 0.05, **P < 0.01 vs. 1w Cont, n = 6).
Effects of CB on masseter muscle activity
The average duty times of masseter muscle activities exceeding 5%, 20%, 50%, or 80% of the day's peak EMG levels were examined at 1 and 2 weeks after implantation of the telemetry system (1w Cont and 2w Cont) and at 1 day, 1 week, and 2 weeks after the subsequent initiation of CB treatment (1d CB, 1w CB and 2w CB) ( Fig. 4: A and B) . The average duty times of all four activity levels in the masseter muscle were not different between 1w Cont and 2w Cont, but those exceeding 20%, 50%, and 80% of the day's peak EMG were significantly increased at 1 day after the CB treatment and remained unchanged at 1 and 2 weeks (P < 0.05 or 0.01 vs. 1w Cont, n = 6) ( Fig. 4: A and B) . The relative duty times expressed as percentages of the values in 1w Cont were not different between 1w Cont and 2w Cont, but in 1d CB, they were significantly increased by approximately 2-fold at the lower activity levels (152% ± 13% and 209% ± 31% exceeding 5% and 20% of the day's peak EMG levels, respectively) and by approximately 6-fold at the higher activity levels (537% ± 156% and 757% ± 230% at activities exceeding 50% and 80% of the day's peak EMG levels, respectively) and the magnitude of the increase was similar in both 1w CB and 2w CB (Fig. 4C ).
Effects of SB on masseter muscle
In order to examine whether the CB (a lipophilic b 2agonist)-mediated masseter muscle hypertrophy, MHC isoform transition toward faster muscle phenotypes, and hyperactivity were induced through direct action on muscle b 2 -AR or via the CNS, we compared these effects of CB with those of SB, a hydrophilic b 2 -agonist (29, 30) . Body weight, masseter muscle mass, and masseter mass to body weight ratio were examined in 2-week SB-treated and age-matched control rats (Fig. 5 ). Body Fig. 5 . Effects of SB on body weight, masseter mass, and fiber diameter at 2 weeks. Body weight (A), masseter muscle mass (B), and masseter mass to body weight ratio (C) in rats treated with SB for 2 weeks (SB) and age-matched control rats (Control). No significant difference in body weight was observed between the Control and SB group (P = NS, not significant, n = 4), while both the masseter muscle mass and the masseter mass to body weight ratio were significantly increased by the SB treatment (*P < 0.05 or **P < 0.01 vs. Control, n = 4). Typical cross-sections of HE staining (D) and the average fiber diameter (E) of masseter muscles in the Control and SB-treated rats. Fiber diameter was significantly increased by SB treatment (Cont vs. SB: 52 ± 1.9 mm vs. 60 ± 2.2 mm, *P < 0.05, n = 4). weight was similar in each group (Control vs. SB: 401 ± 7.9 g vs. 421 ± 19.5 g, P = NS, n = 4) ( Fig. 5A ), but the masseter muscle mass (Control vs. SB: 1336 ± 26.5 mg vs. 1675 ± 112.2 mg, P < 0.05, n = 4) ( Fig. 5B ) and the masseter mass to body weight ratio (Control vs. SB: 3.3 ± 0.03 mg/g vs. 4.0 ± 0.2 mg/g, P < 0.01, n = 4) ( Fig. 5C ) were significantly increased by the SB treatment, indicating that the dose of SB used in this study increased similarly the masseter muscle mass efficiently without altering the body weight (31) , as was the case with the CB treatment. Histological analysis similarly showed no abnormal organization of masseter muscle structure (such as fibrosis) in each group, but the fiber diameter was significantly greater in the SB-treated group than in the controls (Control vs. SB: 52 ± 1.9 mm vs. 60 ± 2.2 mm, P < 0.05, n = 4) ( Fig. 5: D and E) .
Effects of SB on MHC composition of masseter muscle
The average MHC compositions in masseter muscles obtained from 2-week SB-treated and age-matched control rats were examined by SDS-PAGE analysis (Fig. 6 ). The SB treatment promoted transition of MHC isoforms toward faster muscle phenotypes, i.e., the proportion of MHC IIa was significantly decreased from 16% ± 1.4% to 8% ± 1.4% (P < 0.01, n = 4), while that of MHC IIb was also significantly increased from 31% ± 2.1% to 42% ± 2.1% (P < 0.01, n = 4) ( Fig. 6B ).
Effects of SB on masseter muscle activity
The average duty times of masseter muscle activities exceeding 5%, 20%, 50%, or 80% of the day's peak EMG levels were examined at 1 and 2 weeks after implantation of the telemetry system (1w Cont and 2w Cont) and at 1 day, 1 week, and 2 weeks after the subsequent initiation of SB treatment (1d SB, 1w SB, and 2w SB) ( Fig. 7: A and B) . The average duty times of all four activity levels in the masseter muscle were not different between 1w Cont and 2w Cont, but in contrast to the results of CB treatment (Fig. 4) , the average duty times and relative duty times of all four activity levels Fig. 6 . Effects of SB on MHC composition of masseter muscle. Typical SDS-PAGE profiles of MHC isoforms (A) and the average MHC compositions (B) of masseter muscles from SB-treated (SB) and age-matched control (Control) rats. The relative proportion of each MHC isoform is expressed as a percentage of total MHC content (% of total MHC). The proportion of MHC IIa was significantly decreased from 16% ± 1.4% to 8% ± 1.4% (P < 0.01), while that of MHC IIb was significantly increased from 31% ± 2.1% to 42% ± 2.1% (P < 0.01) after the SB treatment (**P < 0.01, n = 4). Fig. 7 . Effects of SB on masseter muscle activity. The average duty times were calculated before and after 2-week SB treatment. The proportions of activities exceeding 5%, 20% (A), 50%, and 80% (B) of the day's peak EMG level were determined. The relative duty times are also expressed as a percentage of the respective value in the 1w Cont group set as 100% (C). The average duty times as well as the relative duty times of all four activity levels in the masseter muscle showed no difference among 1w Cont, 2w Cont, 1d SB, 1w SB, and 2w SB.
were also not different among 1w Cont, 2w Cont, 1d SB, 1w SB, and 2w SB. (Fig. 7C ).
Discussion
Our results show that chronic b 2 -AR stimulation with CB, a lipophilic b 2 -agonist, induced not only slow-to-fast MHC transition and hypertrophy in masseter muscle, as shown previously in skeletal muscle and cardiac muscle (4 -6, 32) , but also an increase of the muscle activity as evaluated in terms of duty time. More importantly, the increase of muscle activity observed at 1 day after the initiation of CB treatment was similar to that at 1 and 2 weeks, implying that CB treatment might induce an early increase of muscle activity prior to the histological change such as hypertrophy. In order to examine whether the CB-mediated effects on the masseter muscle were mediated through direct action on muscle b 2 -AR or via the CNS, we compared these effects of CB with those of SB, a hydrophilic b 2 -agonist (29, 30) . As in the case of CB, SB treatment induced hypertrophy and slow-to-fast MHC isoform transition in the masseter muscle, but it did not increase the muscle activity. These data indicate for the first time that chronic b 2 -stimulation induces hypertrophy and MHC transition towards faster phenotypes in the masseter muscle through direct action on muscle b 2 -AR, but the CB-mediated increase of muscle activity is induced through stimulation of b 2 -AR in the CNS.
Our current study, together with our previous study using a bite-opened model, showed that increment of muscle activity is positively correlated with MHC transition, but the precise relationship may depend on the characteristics of the physiological stimulus (17) (Fig. 8) . Chronic b 2 -AR stimulation with CB and bite-opened mechanical overload both increased muscle activity and induced MHC transition in the masseter, but the direction of the MHC transition is opposite, i.e., the former is slow-to-fast, which is desirable for phasic contraction, and the latter is fast-to-slow, which is desirable for tonic contraction (17) . More importantly, both chronic CB treatment and bite-opened mechanical overload increased the duty time at lower as well as higher activities, as compared to the control (17) . However, the magnitude of the increase was similar at each activity level (i.e., approximately 3-fold increase) in bite-opened rats, Fig. 8 . A schematic model of chronic b2-AR stimulation with CB or salbutamol and bite-opened mechanical overload in masseter muscle. Chronic b2-AR stimulation of masseter muscle with CB (left) or SB (middle) induced the slow-to-fast MHC isoform transition in association with hypertrophy, but only CB increased the duty time (i.e., muscle activity). Bite-opened mechanical overload (right) on masseter muscle induced fast-to-slow MHC isoform transition with hypertrophy and increased the duty time. However, the magnitude of the increase in the duty time was different between CB treatment and bite-opened mechanical overload. The magnitude of the increase of the duty time was similar at each EMG amplitude (approximately 3-fold) in bite-opened rats, whereas the effects of CB treatment was much greater at higher EMG amplitude (approximately 6-fold) than at lower EMG amplitude (approximately 2-fold) owing to stimulation of b2-AR in CNS. Inserts: representative rectified EMGs recorded from masseter muscle in CB-treated and bite-opened rats.
whereas it was much greater at higher activity levels (exceeding 50% and 80% of the day's peak EMG level) rather than at lower activity (exceeding 20% of the day's peak EMG level) after chronic CB treatment. This tendency was already apparent at 1 day after the start of CB treatment and remained unchanged at 1 and 2 weeks.
Many studies have shown that different types of stress induce skeletal muscle hypertrophy with specific functional, molecular, and morphological features (4) . Skeletal muscle hypertrophy can be induced by pathological stimuli (e.g., pressure or volume overload) or physiological stimuli (e.g., developmental growth or exercise training) (33, 34) . It is controversial whether CB-mediated skeletal muscle hypertrophy and slow-tofast MHC transition are beneficial changes in the physiological and biochemical characters of skeletal muscle. CB might attenuate the muscle atrophy and increase stroke power as well as contractile speed (35, 36) . On the other hand, CB has been reported to induce apoptosis and impair function of skeletal muscle, which are similar to the well-known toxic effects of catecholamine (37 -39) . Also, CB is reported to induce cardiovascular side-effects in body-builders, such as tachycardia, which was observed in the current study ( Supplementary  Fig. 4 ), myocardial infarction, and end-stage renal failure (40 -42) . Our current data indicate that CB has therapeutic potential to attenuate the atrophy and improve the function of the masseter muscle with preservation of normal muscle organization, although its clinical application will remain limited until its effects on other tissues, particularly on the cardiovascular system, can be addressed adequately.
Both CB and SB are known to increase muscle strength of the lower limbs in humans (43, 44) . Importantly, the SB-mediated increase of muscle strength is induced via direct action on the muscle b 2 -AR, but the CB-mediated increase of muscle strength might involve a mechanism other than the direct muscle b 2 -AR stimulation, such as cerebral b 2 -AR stimulation, although the mechanisms remain poorly understood (19) . The histological (Figs. 2 and 5) and pathophysiological ( Figs. 4 and 7 ) findings in the current study suggest that b 2 -AR stimulation with CB or SB efficiently induces masseter muscle hypertrophy with slow-to-fast MHC transition via direct stimulation of muscle b 2 -AR and consequently might increase tonic muscle contraction.
Vascular b 2 -AR stimulation in the masseter muscle has been reported to evoke vasodilation in the masseter muscle, and b 2 -AR-mediated vasodilation has been reported to be caused through the upregulation of endothelial nitric oxide synthase via the phosphoinositide 3-kinase-Akt pathway in mouse pulmonary artery or rat cerebral artery (45 -48) . Increased myocardial blood flow has been demonstrated to be pivotal for the development of cardiac hypertrophy and for preventing the transition from cardiac hypertrophy to heart failure because increased myocardial blood flow is essential to maintain the hypertrophied myocardium (49) . More importantly, cerebral blood oxygenation has been demonstrated to be important for rhythmic movement of the masseter muscle, at least in part through increased muscle activity (23, 50) . Taken together, these findings indicate that b 2 -AR-mediated vasodilation in both the masseter and the cerebrum by CB, although not SB, may play an important role in attenuating atrophy of the masseter muscle and improving its function (49) .
It is tempting to speculate that fast-to-slow MHC isoform transition, together with decreased masseter muscle weight and function, impairs rhythmic mandibular movement and may cause serious complications, including dehydration, malnutrition, air flow obstruction, and aspiration pneumonia, which is a major cause of morbidity and mortality in the elderly (9, 51, 52) . These are important issues, as the world's population is aging, and the incidence of aging-related mastication disorders is increasing. Administration of CB does not necessarily lead to improved muscle performance, and in any case, CB toxicities such as hypokalemia and sustained sinus tachycardia observed in the current study need to be further evaluated before the clinical application of CB can be recommended (53, 54) . However, our current findings indicate that a new pharmacological approach to therapy may improve rhythmic movement and contractility by increasing the muscle activity in masseter muscle.
